Mosunetuzumab with or without zanubrutinib for follicular lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies mosunetuzumab alone or combined with zanubrutinib to treat people with follicular lymphoma that is advanced or causing problems. It’s meant to see which approach works better and is safe for long-term treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can sign consent
- Your follicular lymphoma is grade 1, 2, or 3A and has not been treated before
- Your lymphoma needs whole-body (systemic) treatment, not just local treatment
- You have at least one measurable tumor area on CT or MRI (size threshold required)
- You can meet blood/liver/kidney health requirements and get required biopsies
- You do not have certain infections, prior immune-chemo treatments, or major organ/brain/heart problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, mosunetuzumab and zanubrutinib, for people with follicular lymphoma that has come back or not responded to prior treatment. The goal is to see if this combination is safe and effective.
This trial tests a combination of two drugs (mosunetuzumab and zanubrutinib) for people with marginal zone lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help control the lymphoma.
This Phase 2 study tests whether mosunetuzumab, added to lenalidomide, can treat people who have not yet received lymphoma medicines. It’s for follicular lymphoma or marginal zone lymphoma and may help shrink tumors and improve control of the disease.
This trial tests a new drug, mosunetuzumab, given as a shot under the skin for people with a slow-growing type of lymphoma (follicular lymphoma) that has not yet been treated and is not causing heavy symptoms or large tumor masses.
This study tests two new drugs combined together to treat follicular lymphoma (a slow-growing blood cancer). The trial enrolls patients who have never been treated, those with limited disease who want active treatment, and those whose cancer came back or didn't respond to prior therapy.
This trial tests a 3-drug combination (Zanubrutinib, Bendamustine, and Obinutuzumab) for people with advanced follicular lymphoma who have not had treatment before. The goal is to see if a fixed-duration treatment plan can improve outcomes.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.